Market Overview

Why Kiniksa's Stock Is Trading Higher Today

Why Kiniksa's Stock Is Trading Higher Today

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.

Its clinical-stage product candidates include Rilonacept, which is in Phase 2 clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, KPL-045, KPL-404 are other monoclonal antibodies.

Kiniksa Pharmaceuticals shares were trading up 23.01% at $28.33 at the time of publication Monday. The stock has a 52-week high of $28.39 and a 52-week low of $5.01.


Related Articles (KNSA)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at